Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04562129
Title IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors H. Lee Moffitt Cancer Center and Research Institute
Indications

melanoma

Therapies

Aldesleukin + Ipilimumab + Nivolumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.